News | June 01, 2021
Marksans Pharma Q4 FY21 profit up 86%
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
This marks Glenmark's first synthetic decapeptide injectable approval
The product patent has been already filed under fast track approval
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Subscribe To Our Newsletter & Stay Updated
